Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY26 results · Jul–Sep 2025
Tatva Chintan Pharma Chem reported revenue from operations of ₹123.52 crore (up 47.9% from Q2 FY25) and net profit of ₹9.92 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 123.52 | 83.49 | +47.9% | 116.86 | +5.7% |
| Other income | 1.01 | 0.38 | +167.4% | 1.16 | −12.7% |
| Total income | 124.52 | 83.87 | +48.5% | 118.02 | +5.5% |
| Profit before tax | 13.66 | (1.02) | Turned profit | 9.10 | +50.1% |
| Net profit for the period | 9.92 | (0.66) | Turned profit | 6.65 | +49.1% |
| EPS, basic (₹) | 4.24 | (0.29) | Turned profit | 2.84 | +49.3% |
| Net margin (%) | 8.0 | -0.8 | 5.7 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 115.86 | 80.96 | +43.1% | 109.18 | +6.1% |
| Other income | 0.79 | 0.81 | −1.5% | 1.37 | −42.0% |
| Total income | 116.66 | 81.77 | +42.7% | 110.55 | +5.5% |
| Profit before tax | 12.34 | (1.58) | Turned profit | 7.05 | +75.0% |
| Net profit for the period | 8.94 | (1.11) | Turned profit | 5.13 | +74.2% |
| EPS, basic (₹) | 3.82 | (0.47) | Turned profit | 2.19 | +74.4% |
| Net margin (%) | 7.7 | -1.4 | 4.7 |
Consolidated
- Filed with BSE
- 31 Oct 2025, 20:55 IST
- Board meeting
- 31 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Oct 2025, 20:55 IST
- Board meeting
- 31 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE